CARGO Therapeutics, Inc. financial data

Symbol
CRGX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
835 Industrial Road, Suite 400, San Carlos, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.79K %
Debt-to-equity 12.4 %
Return On Equity -38.2 % -133%
Return On Assets -33.9 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46M shares
Common Stock, Shares, Outstanding 41.2M shares +3674%
Common Stock, Value, Issued 46K USD +4500%
Weighted Average Number of Shares Outstanding, Basic 47.7M shares +6265%
Weighted Average Number of Shares Outstanding, Diluted 47.7M shares +6265%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 131M USD +61.6%
General and Administrative Expense 41.2M USD +72.6%
Operating Income (Loss) -172M USD -64.1%
Net Income (Loss) Attributable to Parent -154M USD -93.1%
Earnings Per Share, Basic 76 USD/shares +98.1%
Earnings Per Share, Diluted 76 USD/shares +98.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 71.2M USD +18%
Marketable Securities, Current 334M USD
Assets, Current 410M USD +547%
Property, Plant and Equipment, Net 11.7M USD +27.4%
Operating Lease, Right-of-Use Asset 24.1M USD +752%
Other Assets, Noncurrent 4.65M USD -33.7%
Assets 451M USD +447%
Accounts Payable, Current 5.37M USD -27.7%
Employee-related Liabilities, Current 5.59M USD +114%
Accrued Liabilities, Current 7.53M USD +11.1%
Liabilities, Current 21.6M USD -47.4%
Operating Lease, Liability, Noncurrent 28.4M USD +9380%
Other Liabilities, Noncurrent 225K USD -10%
Liabilities 50.1M USD +20.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 635K USD
Retained Earnings (Accumulated Deficit) -267M USD -136%
Stockholders' Equity Attributable to Parent 401M USD
Liabilities and Equity 451M USD +447%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.1M USD -114%
Net Cash Provided by (Used in) Financing Activities -104K USD -100%
Net Cash Provided by (Used in) Investing Activities -294M USD -47389%
Common Stock, Shares Authorized 500M shares +1624%
Common Stock, Shares, Issued 41.2M shares +3674%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -324M USD -670%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 71.7M USD +18.9%
Deferred Tax Assets, Valuation Allowance 30.4M USD +179%
Deferred Tax Assets, Gross 37M USD +226%
Operating Lease, Liability 28.6M USD +889%
Depreciation 2.33M USD +40%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -41M USD -15.4%
Lessee, Operating Lease, Liability, to be Paid 45.3M USD +1363%
Property, Plant and Equipment, Gross 15.2M USD +44.1%
Operating Lease, Liability, Current 143K USD -94.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.22M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 4.68M USD +94.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure +17.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 16.7M USD +8079%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.44M USD
Deferred Tax Assets, Operating Loss Carryforwards 2.28M USD +83%
Unrecognized Tax Benefits 1.23M USD +41.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.66M USD
Operating Lease, Payments 1.29M USD +185%
Additional Paid in Capital 667M USD +17779%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares